Kymera Therapeutics (KYMR) Current Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Current Leases data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Current Leases rose 9.11% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 9.11% increase from a year earlier, with the FY2025 full-year figure at $11.9 million, up 686.63% from the prior year.
• Current Leases for Q1 2026 stood at $1.7 million, down from $11.9 million in the prior quarter.
• Over the last five years, Current Leases for KYMR reached as high as $11.9 million in Q4 2025 and fell as low as $1.0 million in Q3 2023.
• Historically, Current Leases has averaged $3.4 million across 5 years, with a median of $1.9 million in 2025.
• On a YoY basis, Current Leases climbed as much as 686.63% in 2025 and fell as far as 83.37% in 2025.
• Year by year, Current Leases stood at $1.4 million in 2022, then slipped by 9.3% to $1.3 million in 2023, then climbed by 18.87% to $1.5 million in 2024, then surged by 686.63% to $11.9 million in 2025, then sank by 85.75% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.7 million in Q1 2026, $11.9 million in Q4 2025, and $1.9 million in Q3 2025.